A recent randomized, phase 2 study by Gane, E.J. and colleagues presented at the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2021 demonstrated the high long-term efficacy and safety of tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) antiviral prophylaxis in post-orthotopic liver transplant (OLT) patients with chronic hepatitis B virus (HBV) infection.¹ The renal- and bone-protecting effects on patients with TAF were shown to be more profound than those with TDF.¹

In the 2022 Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Susan Eshleman from the School of Medicine of John Hopkins University, Baltimore of the United States (US), presented a study on human immunodeficiency virus (HIV) screening using ribonucleic acid (RNA) assays in patient

Currently approved human immunodeficiency virus-1 (HIV-1) pre-exposure prophylaxis (PrEP) regimens have been associated with long-term adverse events (AEs) including weight change, loss of bone mineral density, and changes in renal function.¹ 

Thirty months following treatment interruption, a patient known as the "London patient" has continued to remain in sustained remission of human immunodeficiency virus (HIV) status.¹

Advances in the HIV prevention and treatment have increased the likelihood of eliminating the HIV epidemic, although changes in the disease management guidelines have yet to be implemented. Indeed, the HIV experts always emphasize the importance of accessible HIV testing campaigns,

The estimated number of people living with human immunodeficiency virus (HIV) infection was 36.9 million in 2014.¹ An estimated 15.2% of people living with HIV are located in the Asia-Pacific region.²